WS Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q3
Sell
-100,000
Closed -$8.77M 75
2019
Q2
$8.77M Sell
100,000
-50,000
-33% -$4.26M 0.57% 34
2019
Q1
$13.6M Buy
+150,000
New +$12.8M 0.82% 27
2018
Q4
Sell
-50,000
Closed -$4.79M 87
2018
Q3
$4.79M Sell
50,000
-330,000
-87% -$32M 0.16% 61
2018
Q2
$36.2M Buy
+380,000
New +$34.9M 1.02% 23

Other funds holding XBI

WS Management's XBI Position: Q1 2026 in Review

WS Management increased its State Street SPDR S&P Biotech ETF (XBI) stake by 15% in Q1 2026, buying an estimated $2.5M and bringing the position to 150,000 shares worth $19.2M. The position accounts for 1.69% of the portfolio, ranked #20.

WS Management first reported a position in XBI in Q2 2022 and has held it in 16 quarters since. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • WS Management held 150,000 shares of State Street SPDR S&P Biotech ETF worth $19.2M as of Q1 2026.
  • WS Management bought 20,000 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $2.5M.
  • State Street SPDR S&P Biotech ETF made up 1.69% of WS Management's portfolio in Q1 2026, its #20 holding.
  • WS Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2022 and has held it in 16 quarters since.
  • 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on WS Management's 13F filing for Q1 2026, filed 15 May 2026.